Golfyeti

My apologies - I was incorrect - the interim analysis is for PhIII BOM2 - 2023

Here is a summary of the Selected Milestones Graph shown at 5:43 of the presentation:

Q4 2021     PhIII BOMII trial enrollment

                  Initial Cov19 phII data read-out

Q1 2022      Initiate Cov19 PhIII trial

Q2 2022      Topline PhII data read-out for PAH

2H 2022      PhIII data read-out Cov19

Q3 2022      Potential emergency use authorization EAU for Cov19

     2023      BOMII PhIII interim data read out for 300 targeted patients

     2024      Potential BOM FDA Approval due to Breakthrough Therapy Designation 

Chicagoest